Exchange: OTC·Updated 03:57 PM EDT

NKGN NKGen Biotech Inc

$0.011
$0.0001
(0.90%)
Today
Mkt Cap$1.44M
Vol8,000.00

About NKGN

NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.
48

Neutral Sentiment

How do you feel about NKGN?

GoldGhost
$NKGN “Enjoying a glorious day in Tokyo with and the Heka Bio team who are working with to bring our NK cell therapy (troculeucel) to the Japanese market. Under Japan's Yokohama declaration for regenerative medicine, we will soon begin commercial sales and treatment pending official inspections of our Korea and U.S. GMP facilities by the Japanese regulatory authorities. Our goal is to launch later this year.” -Paul Song July 8th, 2026
3
BCINU
$NKGN Chairman Paul Song made an interesting comment on LinkedIn on funding and commitment throughout Asia and Hong Kong.
2
Picklerinthekitchen
$NKGN this company couldn’t get its financials in order to stay listed on Nasdaq but it’s going to run a drug trial ? Let that sink in lol
whereisthebull50
$NKGN Just saw on clinical trial website, they moved phase 3 trial completion dates to 2028. Now I have real doubts about their intentions on randomized trial. 2025, 2026, 2027 now 2028. It seems they like only open label trials. Why?

Advertisement|Remove ads.